Hamilton Capital LLC Reduces Position in AbbVie Inc. $ABBV

Hamilton Capital LLC lowered its position in shares of AbbVie Inc. (NYSE:ABBV) by 89.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,886 shares of the company’s stock after selling 42,429 shares during the period. Hamilton Capital LLC’s holdings in AbbVie were worth $1,278,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ABBV. State Street Corp boosted its stake in AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of AbbVie during the 2nd quarter valued at about $2,905,952,000. Deutsche Bank AG lifted its holdings in AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after acquiring an additional 1,241,587 shares during the period. Finally, Amundi grew its position in AbbVie by 2.4% during the first quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after buying an additional 247,689 shares during the period. Institutional investors own 70.23% of the company’s stock.

Insider Activity

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

AbbVie Trading Up 0.3%

Shares of NYSE:ABBV traded up $0.84 during midday trading on Thursday, hitting $272.20. 5,492,274 shares of the stock were exchanged, compared to its average volume of 6,424,160. The company has a 50 day moving average price of $258.27 and a 200-day moving average price of $235.87. The stock has a market cap of $480.92 billion, a P/E ratio of 76.89, a PEG ratio of 1.22 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $274.94.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the company earned $2.97 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations bolster oncology prospects. AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400), a c-Met-directed antibody-drug conjugate, received two FDA Breakthrough Therapy Designations for colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory review while supporting the value of AbbVie’s growing ADC portfolio. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data adds another potential growth driver. AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result could expand Epkinly’s commercial opportunity if confirmed and approved. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Analysts raised their valuation estimates. JPMorgan increased its AbbVie price target to $300 from $285 and maintained an “overweight” rating. Cantor Fitzgerald also raised its target to $290 from $285 and assigned an “overweight” rating, signaling continued confidence in the company’s pipeline and earnings outlook.
• Neutral Sentiment: Recent operating momentum provides support: AbbVie’s latest reported revenue rose 10.2% year over year to $16.99 billion, while EPS exceeded consensus estimates. However, the stock’s elevated valuation—approximately 77 times earnings—leaves less room for disappointment.
• Negative Sentiment: Dividend sustainability remains a risk. Commentary highlighted a reported payout ratio above 190%, meaning dividends substantially exceed GAAP earnings. Although noncash items and adjusted earnings can distort this measure, investors may remain concerned about long-term dividend coverage and financial flexibility.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research analyst reports. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and lifted their target price for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Piper Sandler lifted their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Morgan Stanley lifted their price target on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. Guggenheim boosted their price target on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. lifted their price target on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $276.64.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.